News Snapshot:
A new COVID-19 vaccine developed by China's Clover Biopharmaceuticals has proven to be 67 percent effective against COVID-19, and 79 percent against the Delta variant in a mass clinical trial, Reuters reported recently. The vaccine "was 67 percent effective against COVID-19 of any degree of severity and 79 percent against the highly infectious Delta variant in a large trial," the international news organization said in a report published Wednesday, citing Clover's statement. Besides, the vaccine was 83.7 percent effective against moderate-to-severe cases in the trial, and in particular, 81.7 percent effective against those moderate-to-severe cases caused by Delta, the report...
